

# Andrew Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5503865/publications.pdf>

Version: 2024-02-01

15  
papers

897  
citations

933264

10  
h-index

1058333

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

1215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.	13.9	447
2	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	2.1	145
3	The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries. <i>Aids</i> , 2018, 32, 1551-1561.	1.0	96
4	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. <i>Nature Communications</i> , 2020, 11, 5922.	5.8	55
5	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. <i>Aids</i> , 2020, 34, 2259-2268.	1.0	30
6	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. <i>Journal of the International AIDS Society</i> , 2019, 22, e25352.	1.2	25
7	Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. <i>Aids</i> , 2021, 35, S127-S135.	1.0	21
8	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	20
9	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 16-24.	1.3	20
10	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. <i>Aids</i> , 2021, 35, S117-S125.	1.0	12
11	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. <i>Aids</i> , 2021, 35, 205-211.	1.0	11
12	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 106-114.	1.5	7
13	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. <i>Aids</i> , 2020, 34, 321-324.	1.0	4
14	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	4
15	High individual pain variability in people living with HIV: A graphical analysis. <i>European Journal of Pain</i> , 2021, 25, 160-170.	1.4	0